Switch to Bictegravir/Emtricitabine/Tenofovir Alafenamide After Renal Transplant
Status:
Recruiting
Trial end date:
2022-12-01
Target enrollment:
Participant gender:
Summary
This is an open-label study, where participants will be switched from their current HIV
medication to the study drug, Biktarvy. Open-label means both the investigator and the
participant will know what drug will be given. Participants will be followed for 48 weeks in
order to monitor the efficacy, safety and tolerability of Biktarvy. The investigator
hypothesizes that Biktarvy will be an important addition to the management of HIV-positive
post renal transplant patients, especially since it is a one pill daily dosing regimen,
thereby decreasing the pill burden in this population.